Clinical Trial Update: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

KO-2806 is being studied in Phase 1 trials as a monotherapy and in combination regimens for advanced solid tumors, including HRAS-altered cancers and Non-Small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Colorectal Cancer
• Non-clear Cell Renal Cell Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Renal Cell Carcinoma
• Solid Tumors with Hras Alterations

Drugs mentioned

• KO-2806

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Status: RECRUITING